Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deuterium butylbenazine for tardive dyskinesia in schizophrenia
ChiCTR2500106481Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of deutetrabenazine in tardive dyskinesia (TD) (4 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Positive and Negative Symptom Score Sheet (PANSS) and Involuntary Movement Scale (AIMS). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
deutetrabenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on ChiCTR2500106481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106481.